Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice
Pharmaceuticals · 17.09.2025 · 18 (9) · 1399
DOI: 10.3390/ph18091399 ↗Kurz gefasst
Kommentar in der Zeitschrift Pharmaceuticals, online erschienen am 17.09.2025. Verfasst von Giuliana Ciappina und 11 weiteren Autor:innen. Beteiligte Einrichtung: Section of Experimental Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The introduction of novel oncologic therapies, including targeted agents, immunotherapies, and antibody–drug conjugates, has transformed the therapeutic landscape of cancer care. This evolution has resulted in a dual clinical scenario; while survival outcomes have markedly improved, leading to a growing population of long-term cancer survivors, an increasing incidence of previously unrecognized treatment-related toxicities has emerged. Among these, cardiovascular adverse events represent some of the most prevalent and clinically significant complications observed in both conventional chemotherapy and modern therapeutic regimens. Cardiotoxicity has become a major concern, with the potential to adversely affect not only cardiovascular health but also the continuity and efficacy of oncologic treatments, thereby impacting overall survival. This opinion paper synthesizes current evidence, identifies critical gaps in knowledge, and advocates for a multidisciplinary, evidence-based framework to guide the prevention, early detection, and optimal management of cardiotoxicity associated with anticancer therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Experimental Medicine, Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy.
- Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy.
- School of Specialization in Medical Oncology, Department of Human Pathology "G. Barresi", University of Messina, 98122 Messina, Italy.
- Division of Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Naples, Italy.
- Department of Human Pathology in Adult and Developmental Age 'Gaetano Barresi', University of Messina, 98122 Messina, Italy.
- Division of Medical Oncology, AOU "G. Martino" Hospital, University of Messina, 98125 Messina, Italy.
ORCID-Profile: Giuliana Ciappina, Luigi Colarusso, Alessandro Ottaiano, Tindara Franchina, Antonio Picone, Chiara Barraco, Antonio Ieni, Maurizio Cusmà Piccione, Concetta Zito, Massimiliano Berretta
Zitieren
APA
Ciappina, G., Colarusso, L., Maiorana, E., Ottaiano, A., Franchina, T., Picone, A., Facchini, G., Barraco, C., Ieni, A., Cusmà Piccione, M., Zito, C., & Berretta, M. (2025). Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice. Pharmaceuticals, 18(9), 1399. https://doi.org/10.3390/ph18091399
Vancouver
Ciappina G, Colarusso L, Maiorana E, Ottaiano A, Franchina T, Picone A, et al. Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice. Pharmaceuticals. 2025;18(9):1399. doi:10.3390/ph18091399
BibTeX
@article{Ciappina2025,
author = {Ciappina, Giuliana and Colarusso, Luigi and Maiorana, Enrica and Ottaiano, Alessandro and Franchina, Tindara and Picone, Antonio and Facchini, Gaetano and Barraco, Chiara and Ieni, Antonio and Cusmà Piccione, Maurizio and Zito, Concetta and Berretta, Massimiliano},
title = {Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {9},
pages = {1399},
doi = {10.3390/ph18091399}
}
EUVIMED